GASTRIC MOTILITY DISORDER DRUG MARKET Size and trends

Gastric Motility Disorder Drug Market Size and Trends

The gastric motility disorder drug market is estimated to be valued at USD 60.88 Bn in 2025 and is expected to reach USD 89.22 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.

To learn more about this report, Request sample copy

The market is experiencing positive growth due to the increasing prevalence of gastric motility disorders worldwide. Various factors such as the growing geriatric population, changing lifestyle habits, and dietary changes are contributing to the rising cases of gastric disorders. Moreover, the ongoing development of novel and advanced drugs for the treatment of gastric motility disorders is further supporting the market growth. However, the expiry of patents of major drugs and stringent regulations for drug approval may hamper the market growth during the forecast period.

Rising incidence of gastric disorders

The global prevalence of gastric motility disorders has been increasing steadily over the past few decades. Various factors such as changing lifestyle patterns, unhealthy diets, and higher levels of stress have significantly contributed to the rising incidence of gastric issues across both developing and developed regions. People are leading increasingly hurried and stressful lives which is negatively impacting the functioning of their digestive system. Additionally, certain medical conditions like diabetes, neurological disorders, and gastric surgeries can predispose patients to developing gastric motility dysfunction over time. The growing patient pool of chronic gastric disorders indicates a growing need for more effective treatment options. Currently available medications are often found to produce unsatisfactory results or come with intolerable side-effects in many cases.